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Abstract
Tissue kallikrein (KLK1) expression is up-regulated in human diabetic kidney tissue and induced by high glucose (HG) in
human proximal tubular epithelial cells (PTEC). Since the kallikrein-kinin system (KKS) has been linked to cellular
inflammatory process in many diseases, it is likely that KLK1 expression may mediate the inflammatory process during the
development of diabetic nephropathy. In this study, we explored the role of KLK1 in tubular pro-inflammatory responses
under the diabetic milieu. Recombinant KLK1 stimulated the production of inflammatory cytokines in PTEC via the
activation of p42/44 and p38 MAPK signaling pathways. Molecular knockdown of endogenous KLK1 expression by siRNA
transfection in PTEC attenuated advanced glycation end-products (AGE)-induced IL-8 and ICAM-1 productions in vitro.
Interestingly, exposure of PTEC to KLK1 induced the expression of protease-activated receptors (PARs). There was a 2.9-fold
increase in PAR-4, 1.4-fold increase in PAR-1 and 1.2-fold increase in PAR-2 mRNA levels. Activation of PAR-4 by a selective
agonist was found to elicit the pro-inflammatory and pro-fibrotic phenotypes in PTEC while blockade of the receptor by
specific antagonist attenuated high glucose-induced IL-6, CCL-2, CTGF and collagen IV expression. Calcium mobilization by
the PAR-4 agonist in PTEC was desensitized by pretreatment with KLK1. Consistent with these in vitro findings, there was a
markedly up-regulation of tubular PAR-4 expression in human diabetic renal cortical tissues. Together, these results suggest
that up-regulation of KLK1 in tubular epithelial cells may mediate pro-inflammatory pathway and PAR activation during
diabetic nephropathy and provide a new therapeutic target for further investigation.
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Introduction
Diabetic nephropathy (DN) is a chronic, progressive renal
disease that develops in approximately one third of people with
diabetes. It is also the leading cause of end-stage renal disease
(ESRD) in developed countries. In addition to pathognomonic
features of glomerular hypertrophy, basement membrane thick-
ening and mesangial matrix expansion, increasing evidence from
numerous experimental and clinical studies of DN has demon-
strated the participation of different inflammatory molecules and
pathways. These data indicate that tubulointerstitial inflammation
plays a critical role in the progression of DN to ESRD [1–3].
Inflammatory cytokines, mainly interleukin 1(IL-1), interleukin 6
(IL-6), interleukin 8 (IL-8) and tumor necrosis factor a (TNFa) are
involved in the development of and progression to interstitial
fibrosis in both diabetic patients and experimental models [4,5].
Up-regulation of intercellular adhesion molecule 1 (ICAM-1) and
chemokine (C-C motif) ligand 2 (CCL-2) leads to inflammatory
cell recruitment and activation in the diabetic kidney [6]. In
addition to cytokine production, induction of growth factors, such
as insulin-like growth factor 1 (IGF-1), hepatocyte growth factor
(HGF), transforming growth factor b (TGFb) and connective tissue
growth factor (CTGF) in proximal tubules enhances the activation
and proliferation of myofibroblasts and collagen deposition,
eventually resulting in interstitial fibrosis [7,8]. In our previous
studies, we have shown that high glucose (HG) stimulates IL-6 and
CCL-2 expression via PKC activation and ERK1/2 signaling in
cultured proximal tubular epithelial cells (PTEC) [9]; and
advanced glycated end-products (AGE) and their carbonyl
intermediates induce tubular IL-8, ICAM-1 expression via NFkB,
ERK1/2 and STAT-1 signal transduction [10,11]. These data
suggest that HG, AGE and their intermediates play a pivotal role
in the pathogenesis of diabetic tubular inflammation.
In fact, renal dysfunction correlates better with tubular and
interstitial lesions than with glomerular changes [12]. Proximal
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tubules have been identified to be responsible for the change in
urinary albumin excretion, which is independent of glomerular
permeability changes during the very early stage of DN [13].
Other studies have also demonstrated the correlation between the
induction of inflammatory markers and the degree of albuminuria
prior to the development of fibrosis. The current therapeutic
approaches have not been successful in preventing the progression
of DN to ESRD. Thus, understanding the mechanisms of the
underlying inflammatory pathways in DN is an important
prerequisite for the development of more effective therapeutic
strategies for the prevention of this relentless attrition of renal
function in DN.
The kallikrein-kinin system (KKS) has been associated with
inflammation, coagulation, pain and vascular permeability
through the generation of kinins. Tissue kallikrein (KLK1), one
of the components of KKS, is a serine protease that cleaves low
molecular weight kininogen into kinin, which exerts the biological
functions through kinin receptor, B1R and B2R signaling [14,15].
We have previously shown that KKS is involved in the
pathogenesis of DN. High glucose induced KLK1 and B2R
expression in cultured PTEC and in human proximal tubules of
the diabetic kidney [9]. Further in vivo data showed that treatment
of the diabetic db/db mice with icatibant, a B2R antagonist,
partially attenuated proteinuria and histological lesions in renal
tissues [16]. In addition, the deletion of B2R protected against the
development of streptozotocin (STZ)-induced DN [17]. These
results suggested that tubular KLK1 expression may play a
deleterious role during DN.
Although most of the biological functions of KLK1 are
mediated by kinin receptor signaling, recent studies suggest that
KLK1 may also activate protease activated receptors (PARs) in
inflammatory and cardiovascular diseases [18,19]. PARs are a
subfamily of G protein-coupled receptors that are activated or
inhibited by serine protease to expose a tethered ligand that binds
to the receptor for signal transduction. There are four known
members in the family, in which PAR-1 and PAR-3 are activated
mainly by thrombin, PAR-2 is activated by trypsin and PAR-4 is
activated by both enzymes [19,20]. Other enzymes of the
coagulation cascade such as tissue factors VIIa/Xa and activated
protein C are also shown to be regulators of PARs [21]. Activation
of the coagulation cascade occurs in the course of diabetic mellitus
that affect fibrinolysis, platelet and endothelial functions. Fibrin
Figure 1. Recombinant KLK1 induced both cytokine expression and MAPK activation in tubular cells. PTEC was incubated with 10 nM
and 100 nM KLK1 for 6 h and 24 h, gene and protein expression was determined by real-time PCR and ELISA respectively. KLK1 increased IL-6, CCL-2,
IL-8 and ICAM-1 mRNA (A) and protein (B) expression. PTEC was incubated with 100 nM KLK1 for the indicated duration, and expression of MAPK
signaling molecules was detected by Western blot analysis. KLK1 increased phosphorylated p38 (C) and phosphorylated p42/44 (D) MAPK signaling
pathways. *p,0.05; ***p,0.001 compared with control.
doi:10.1371/journal.pone.0088894.g001
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deposition is commonly observed in tubulointerstitial damage of
DN. PAR-2 expression was increased in proximal tubuli in IgAN
nephropathy [22] and there was an up-regulation of PAR-1
expression in experimental diabetic glomerulosclerosis [23]. All
these data indicated that the coagulation system may also play an
important role in renal damage.
In this study, we investigated the role of KLK1 in tubular pro-
inflammatory responses in cultured human PTEC and examined
the role of PAR-4 activation in KLK1-mediated signaling in the
development of DN.
Materials and Methods
Ethics Statement
The use of archival renal tissue for this study was approved by
the Research Ethics Committee/Institutional Review Board of the
University of Hong Kong/Hospital Authority Hong Kong West
Cluster. The Institutional Review Board waived the need for
consent for using these specimens.
Reagents
Renal epithelial cell basal medium (REBM) and growth
supplement were from Lonza Walkersville, MD. Recombinant
human kallikrein (KLK1) was from ProSpec, Israel. PAR-4 agonist
(AYPGKF-NH2) and PAR-4 antagonist (tcY-NH2) were from
Tocris Bioscience, Ellisville, MO. AGE-BSA and D-glucose were
from Sigma-Aldrich, St. Louis, MO. SYBR Green Master Mix
was from Applied Biosystems, Carlsbad, CA. LipofectamineTM
2000 and TRizol reagent were from Invitrogen, Carlsbad, CA.
Renal Biopsies
Archival renal biopsies obtained from 5 patients with biopsy-
proven DN (mean age of patients: 55; mean DM duration: 6.2 yrs;
mean HbA1C: 7.2%; mean serum creatinine: 464 mmol/L; mean
proteinuria: 5.80 g/24 h) were selected for this study. Normal
portions of renal tissues removed from 5 archival nephrectomy
specimens for the treatment of renal carcinoma (mean age of
patients: 61; mean serum creatinine: 87.8 mmol/L) were used as
control.
Figure 2. KLK1 mediated AGE-BSA induced IL-8 and ICAM-1 expression in PTEC. Cells were incubated with 0.1 or 0.5 mg/ml AGE-BSA for
6 h, and gene expression was determined by real-time PCR analysis. AGE induced KLK1 mRNA expression in PTEC (A). Cells were transfected with
KLK1-specific siRNA, and the endogenous protein level was determined by Western blot analysis (B). Transfected cells were incubated with 0.5 mg/ml
AGE for 48 h, and protein expression of cytokine was detected in culture medium by ELISA. AGE -induced IL-8 (C) and ICAM-1 (D) protein expression
was inhibited by KLK1 gene silencing. ***p,0.001 compared with control, dP,0.05 compared with mock transfection and #p,0.05; ##p,0.01
compared with mock transfection incubated with AGE.
doi:10.1371/journal.pone.0088894.g002
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Figure 3. Increased expression of PAR-4 by KLK1 and HG in PTEC. Cells were incubated with 10 nM and 100 nM KLK1 for 6 h, and gene
expressions of PARs were determined by real-time PCR analysis. KLK1 induced PAR-4 mRNA expression in a dose-dependent manner (A). Cells were
incubated with 30 mM HG for the indicated duration, and gene expression of PARs was determined by real-time PCR analysis. HG induced PAR-1,
PAR-2 and PAR-4 mRNA expression (B) and protein expression (C) in a time-dependent manner. *p,0.05; **p,0.01; ***p,0.001 compared with
control.
doi:10.1371/journal.pone.0088894.g003
Table 1. Clinical data and tubular scoring of PARs in diabetic nephropathy patients and non-diabetic control subjects.
Patient type
Age/Gender
at biopsy HbA1C (%)
Serum
creatinine
(mmol/L)
Urine protein
excretion (g)
per 24 h Immunohistochemical staining score*
PAR-1 PAR-2 PAR-3 PAR-4
Non-diabetic control group
1 53/F 7.9 97 ,0.03 0 2 1 0
2 47/M N/A 70 ,0.03 0 1 0 1
3 78/F N/A 71 N/A 1 1 0 1
4 53/M N/A 114 100 mg/dL 0 1 1 0
5 74/M N/A 87 ,0.03 1 1 1 1
Diabetic nephropathy group
6 50/M 9.3 227 1.97 0 4 1 4
7 47/M 6.6 844 4.92 1 2 1 3
8 65/M 5.9 750 6.05 2 4 2 2
9 50/M 7.9 215 11.30 1 3 1 2
10 65/F 6.2 284 4.74 1 3 0 2
* quantified on a scoring system 0–5 in which 0 = no cortical staining; 1 =,10% cortical staining; 2 = 10–20% cortical staining; 3 = 20–40% cortical staining; 4 = 40–60%
cortical staining; 5 =.60% cortical staining.
doi:10.1371/journal.pone.0088894.t001
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Cell Culture
Human renal PTEC (Lonza) were cultured REBM with growth
supplement at 37uC in 5% CO2 and 95% air. In all experiments,
cells were used between passages 2–4 and were growth-arrested in
serum free medium for 24 h before stimulation. Confluent, growth
arrested PTEC were incubated in serum free medium containing
10–100 nM recombinant KLK1, 100–200 mM selective PAR-4
agonist (AYPGKF-NH2), 30 mM HG or 500 mg/ml AGE-BSA.
To investigate whether HG/KLK1-induced cytokine expression
was PAR-4 dependent, cells were pre-treated with 10 mM selective
PAR-4 antagonist (tcY-NH2) for 1 h prior to HG/KLK1
stimulation.
Gene Silencing by siRNA Transfection
PTEC were transfected with KLK1 or negative control of
SilenceHSelect Pre-designed siRNA (Applied Biosystems) using
LipofectamineTM 2000 according to manufacturer’s instructions.
The knockdown efficiency of KLK1 was determined by real-time
PCR and Western Blot analysis. After 24 h transfection, cells were
starved with serum free medium prior to AGE treatment.
RNA Extraction and Real-time PCR Analysis
Total RNAs were isolated from PTEC using TRizol reagent.
Two micrograms of total RNAs were reverse transcribed to cDNA
and were amplified using SYBR Green Master Mix. The mRNA
expression was analyzed by ABI 7500 Real-Time PCR System
(Applied Biosystems). Primer sequences used were: IL-6, forward-
ATG AAC TCC TTC TCC ACA AG and reverse-TGT CAA
TTC GTT CTG AAG AG; CCL-2, forward-GAT CTC AGT
GCA GAG GCT CG and reverse-TGC TTG TCC AGG TGG
TCC AT; IL-8, forward-GTG CAG TTT TGC CAA GGA GT
and reverse-TAA TTT CTG TGT TGG CGC AG; ICAM-1,
forward-GGC CTC AGT CAG TGT GA and reverse-AAC CCC
ATT CAG CGT CA; TGFb forward-CAC GTG GAG CTG
TAC CAG AA and reverse-GAA CCC GTT GAT GTC CAC
TT; CTGF, forward-GGA AAA GAT TCC CAC CCA AT and
reverse-TGC TCC TAA AGC CAC ACC TT; PAR-1, forward-
GCC AGA ATC AAA AGC AAC AAA and reverse-TCA TTT
TTC TCC TCA TCC TCC; PAR-2, forward-TGC TAG CAG
CCT CTC TCT CC and reverse-CCA GTG AGG ACA GAT
GCA GA; PAR-3, forward-GCT CAT CCT CTG CCT TCC
and reverse-AAG TTA ATG GGC TTT CCT GC; PAR-4,
forward-GGG TCC CTT CCC CCA CTT and reverse-GAC
AGT TGT AAC AAC CCT ATT TCC AAA; KLK1, forward-
GCC AAG CAG ACG AGG ACT AC and reverse-TTT GAG
GTC CAC ACA CTG GA. Relative gene expression was
obtained after normalization with b-actin, and followed by
comparison to medium control using SDS software (Applied
Biosystems).
Calcium Mobilization
Intracellular calcium measurement was performed using Fluo-4
directTM calcium assay kit (Invitrogen). Cells were grown at 26104
per well in 96-well cell culture plates for 24 h (Corning Costar,
Figure 4. Representative immunohistochemical staining of PAR-1, PAR-2, PAR-3 and PAR-4 in human renal biopsies. Expression of
PARs was demonstrated in renal tissue from patients with biopsy proven diabetic nephropathy (F–I) and non-diabetic control subjects (A–D). Isotype-
matched negative control was shown in diabetic nephropathy section (J) and non-diabetic control (E). Magnification: 400X. Quantitative analysis of
PAR staining by Image Pro Plus 6.0 software (K); IOD, Integrated Optical Density. **p,0.01; ***p,0.001 compared with control.
doi:10.1371/journal.pone.0088894.g004
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Corning, NY) and then incubated with equal volume of 2X Fluo-4
directTM calcium reagent loading solution (Fluo-4 containing
Hanks’ balanced salt solution, 20 mM HEPES, 5 mM probenecid,
pH 7.3) for 1 h at 37uC. Fluo-4 fluorescence signal of labeled cells
was measured using FLUOStar Omega plate reader (BMG
labtech, Germany) for excitation at 485 nm and emission at
520 nm. Baseline signal was recorded for 10 sec, followed by the
initiation of calcium mobilization with the addition of recombinant
KLK1 (50–200 nM) and PAR-4 agonist AYPGKF-NH2 (100–
300 mM) using the onboard reagent injector. For cross desensiti-
zation study, fluo-4-labeled cells were pretreated with KLK1 (100–
200 nM) for 10 min prior to fluorescence measurement.
Detection of Cytokines by ELISA
For cytokine expression analysis, culture medium was collected
after 48 h treatment. IL-6, CCL-2, IL-8 and ICAM-1 protein
levels were quantified using commercial kit (PeproTech, Rocky
Hill, NJ) according to manufacturer’s instructions. The detection
sensitivity range is 24–1500 pg/ml for IL-6, 16–1000 pg/ml for
CCL-2, 8–1000 pg/ml for IL-8 and 23–3000 pg/ml for ICAM-1.
Western Blot Analysis
Cells were lysed with lysis buffer containing protease inhibitor
cocktails (Sigma-Aldrich) as described previously [9,24]. Equal
amount of proteins were resolved in 12% SDS-PAGE gel and
transferred to PVDF membrane (Millipore, Bedford, MA). The
membranes were incubated overnight with antibodies against
PAR-1, PAR-2, PAR-3, PAR-4, CTGF (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), Col IV, KLK1 (Abcam, Cambridge, UK),
phosphor-p42/44 MAPK, p42/44 MAPK, phosphor-p38 MAPK
and p38 MAPK (Cell Signaling Technology, Beverly, MA) in 5%
non-fat milk, and subsequently incubated with peroxidase
conjugated secondary antibodies (Dako, Carpinteria, CA). The
immunocomplex was visualized with ECL prime chemilumines-
cence (GE Healthcare, Buckinghamshire, UK) using ChemiDoc
XRS+ system (Bio-Rad, Hercules, CA). Quantification of protein
bands was performed by the ImageJ program (NIH, Bethesda,
MD) and was normalized to actin level.
Immunohistochemistry
Expression of PARs was examined on paraffin-embedded
human renal tissue section (4 mm) by immunohistochemical
analysis. Briefly, deparaffinized and rehydrated sections were
subjected to microwave-based antigen retrieval in 10 mM citrate
buffer solution (pH 6) for 10 min, followed by quenching in 1%
hydrogen peroxide solution for 10 min. The sections were then
blocked with 2% BSA blocking buffer for 1 h and stained
overnight with antibodies against PAR-1, PAR-2, PAR-3 and
PAR-4 (Santa Cruz Biotechnology). The stained sections were
further incubated with peroxidase conjugated secondary antibod-
ies (Dako). The immunocomplex were visualized using DAB
substrate from Envision Plus system (Dako). All sections were
counterstained with hematoxylin before mounting. PARs staining
were scored on 0–5 scoring system (0= no cortical staining; 1 =,
10% cortical staining; 2 = 10–20% cortical staining; 3 = 20–40%
cortical staining; 4 = 40–60% cortical staining; 5 =.60% cortical
staining) and were quantified by Image Pro Plus 6.0 software
Figure 5. Activation of PAR-4 by selective agonist induced pro-inflammatory and pro-fibrotic responses in PTEC. Cells were incubated
with PAR-4 agonist AYPGKF-NH2 (AP4) for the indicated duration and doses, and gene and protein expression was determined by real-time PCR and
ELISA respectively. PAR-4 agonist increased IL-6, CCL-2, IL-8 and ICAM-1 mRNA expressions in a dose- (A) and time- (B) dependent manner. PAR-4
agonist increased CTGF, but not TGFb mRNA expression in a dose- (C) and time- (D) dependent manner. PAR-4 agonist induced IL-6, CCL-2, IL-8 and
ICAM-1 protein secretion (E). *p,0.05; **p,0.01; ***p,0.001 compared with control.
doi:10.1371/journal.pone.0088894.g005
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(Media Cybernetics, Silver Spring, MD). Data were expressed as
integrated optical density (IOD).
Statistical Analysis
All data were expressed as mean6SD from three independent
experiments. Difference between multiple groups was evaluated by
one-way ANOVA with Bonferroni’s comparison using GraphPad
Prism, version 4 (GraphPad Software, San Diego, CA). Data were
considered statistically significant at p,0.05.
Results
Tissue Kallikrein (KLK1) Induced Pro-inflammatory
Cytokine Expression in PTEC via MAPK Signaling Pathway
We have previously reported that KLK1 expression was up-
regulated in the proximal tubules of human diabetic kidney and
induced in vitro by HG in PTEC [9]. Here, we investigated the
pro-inflammatory effect of KLK1 in cultured PTEC. Recombi-
nant KLK1 at a dose of 100 nM significantly up-regulated the
mRNA and protein expression of IL-6, CCL-2, IL-8 and ICAM-1
(Fig. 1A & 1B). KLK1 also activated phosphorylation of p38 and
p42/44 MAPK signaling proteins (Fig. 1C & 1D).
KLK1 Mediated AGE-induced Pro-inflammatory
Responses in PTEC
AGE stimulated expression of IL-8 and CCL-2 in renal tubular
cells [10], these chemokines recruit leukocyte infiltration into the
renal interstitial space, leading to the development of DN. Since
KLK1 can stimulate the production of cytokines in PTEC, we
next examined whether KLK1 participated in AGE-induced pro-
inflammatory phenotype of PTEC. As shown in Fig. 2A, AGE
(0.5 mg/ml), but not the equivalent dose of BSA, stimulated the
transcript of KLK1 in PTEC. To study the role of KLK1 on
AGE-induced cytokine production, cells were transfected with
Figure 6. PAR-4 mediated HG-induced IL-6 and CCL-2 expression via p42/44 MAPK signaling in PTEC. Cells were pre-treated with 10 mM
selective PAR-4 antagonist, (tcY-NH2) for 1 h before treatment with 30 mM HG. Western blot analysis showed an increase in phosphorylated p42/44
MAPK signaling by HG, which was partially inhibited by tcY-NH2 (A). HG-induced protein synthesis of IL-6 and CCL-2, detected by ELISA, was
attenuated by tcY-NH2 (B). HG-induced CTGF and collagen IV up-regulation, detected by Western blot analysis, was attenuated by tcY-NH2 (C). *p,
0.05; **p,0.01; ***p,0.001 compared with control and #p,0.05; ##p,0.01 compared with cells incubated with HG only.
doi:10.1371/journal.pone.0088894.g006
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control or KLK1 siRNA, and then subjected to AGE stimulation.
Western blot analysis showed that transfection with KLK1 siRNA
significantly decreased endogenous KLK1 protein expression in
PTEC (Fig. 2B) when compared with that of control siRNA.
Knockdown of KLK1 attenuated AGE-induced IL-8 and ICAM-1
secretions in PTEC (Fig. 2C & 2D). These data suggested that
endogenous KLK1 plays a role in mediating AGE-induced pro-
inflammatory responses.
Increased Expression of Protease-Activated Receptor 4
(PAR-4) by KLK1 and HG Stimulation
Recent studies showed that KLK1 can directly stimulate cell
proliferation and migration through protease-activated receptors
(PARs) [25,26]. We next explored the participation of PARs in
mediating the pro-inflammatory effect of KLK1 in PTEC. Real-
time PCR analysis showed a marked induction of PAR-4 mRNA
expression by 2.4 folds and 2.9 folds with 10 nM and 100 nM
KLK1 stimulation, respectively (Fig. 3A). There was no significant
change in PAR-1, PAR-2 and PAR-3 mRNA expression under the
same condition. In addition to KLK1, incubation of PTEC with
HG (30 mM) also increased PAR-1, PAR-2 and PAR-4 mRNA
expression by 1.5 folds, 1.2 folds and 1.8 folds respectively, when
compared to control (Fig. 3B). Similarly, the up-regulation of
PAR-1, PAR-2 and PAR-4 proteins by HG was demonstrated by
Western blot analysis (Fig. 3C) after 24-h and 48-h incubation.
Increased Tubular PAR-2 and PAR-4 Expressions in
Human Renal Biopsies from Patients with Diabetic
Nephropathy (DN)
As PAR expression has been implicated in the pathogenesis of
many inflammatory diseases [27–30] and some renal disorders
[22,23], we evaluated the expression of all PARs in renal biopsies
from both DN patients and non-diabetic control subjects by
immunohistochemical staining (IHC). Table 1 showed the clinical
data of the study subjects and the intensity of PAR immunostain-
ing in their kidney tissues. In normal subjects, mildly positive
staining for PAR-2 was observed in the renal cortex, mostly in
vascular and tubular cells (score 1–2), whereas only little staining
was detected in the glomerulus (Fig. 4B). In DN biopsies, there was
intense PAR-2 expression in the proximal tubules (score 2–4) and
to a lesser extent in the glomeruli (Fig. 4G). In contrast, PAR-1,
PAR-3 and PAR-4 (score 0–1) staining was barely detectable in
normal renal cortex (Fig. 4A, 4C & 4D). Strong staining for PAR-4
(score 2–4) was detected in most proximal tubules but not
glomeruli of DN biopsies (Fig. 4I). On the other hand, there was
no appreciable difference in PAR-1 and PAR-3 immunostaining
between DN and control specimens (Fig. 4F & 4H). Isotype-
matched control on DN section (Fig. 4J), non-diabetic control
(Fig. 4E) and control omitting the primary antibodies (data not
shown) showed negative staining throughout.
Activation of PAR-4 Induced Pro-inflammatory and Pro-
fibrotic Responses in PTEC
The up-regulation of tubular PAR-4 expression in response to
HG led us to investigate whether or not the activation of PAR-4
was implicated in the inflammatory pathway. We first studied the
ability of the PAR-4 agonist, AYPGKF-NH2, to induce inflam-
matory response in PTEC. Treatment of PTEC with AYPGKF-
NH2 resulted in a significant induction of IL-6, CCL-2, IL-8 and
ICAM-1 mRNA expression in a dose- and time-dependent
manner (Fig. 5A & 5B) by real-time PCR analysis. Maximal up-
regulation of all these genes occurred at 3 h after stimulation.
Since PAR-1 and PAR-2 activation has been described in the
promotion of tissue fibrosis via the production of connective tissue
growth factor (CTGF) and thus the accumulation of extracellular
matrix (ECM) proteins [31–33], we examined the effect of PAR-4
activation on the expression of pro-fibrotic factors. Exposure of
PTEC to AYPGKF-NH2 did not affect TGFb mRNA expression,
but significantly increased CTGF expression (Fig. 5C & 5D). The
Figure 7. Intracellular calcium mobilization by KLK1 and PAR-4
agonist in PTEC. Cells were incubated with Fluo-4 directTM reagent
solution at 37uC for 1 h and the fluorescence signals induced by the
addition of recombinant KLK1 at the indicated concentrations were
measured (A). Fluorescence signal induced by the addition of the PAR-4
agonist AYPGKF-NH2 (AP4) at the indicated concentrations (B).
Fluorescence signal of PAR-4 agonist-induced calcium response in
cross desensitization study. Cells were untreated or pretreated with
100 nM or 200 nM KLK1 for 10 min prior to AP4 stimulation (C). (q)
indicates the time at which agonist was added. Data are representative
of three independent experiments.
doi:10.1371/journal.pone.0088894.g007
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increased cytokine secretion was detected in culture medium after
24-h incubation with AYPGKF-NH2 (Fig. 5E). To confirm our
hypothesis that PAR-4 activation is involved in HG-induced
tubular pro-inflammatory and pro-fibrotic pathways, PTEC was
pretreated with a PAR-4 antagonist, tcY-NH2 prior to HG
incubation. Since we and others have shown that induction of IL-
6, CCL-2 and CTGF expression by HG are mediated via p42/44
MAPK signaling in human PTEC [9], the expression level of
phosphorylated p42/44 protein was determined. Western blot
analysis showed that blockade of PAR-4 by PAR-4 antagonist
inhibited HG-induced p42/44 phosphorylation (Fig. 6A) and
attenuated the subsequent increase in IL-6 and CCL-2 protein
synthesis as measured by ELISA (Fig. 6B). In addition, PAR-4
antagonist also inhibited HG-induced CTGF and collagen IV
expression (Fig. 6C).
KLK1 Mediated Pro-inflammatory Responses through
PAR-4 Activation
Our findings on the up-regulation of PAR-4 by KLK1 suggest
the involvement of PAR-4 in KLK1 signaling. Since it has been
reported that members of the KLK family can activate PARs by
proteolytic cleavage of the N-terminal extracellular domain, and
release of a tethered ligand for receptor binding, we next
investigated the ability of KLK1 in the activation of PAR-4 using
calcium mobilization studies. First, the addition of KLK1 or the
selective PAR-4 agonist each elicited a calcium influx response in
PTEC in a dose-dependent manner (Fig. 7A & 7B). These data
indicate that KLK1 signaling involves an increase in intracellular
calcium concentration, and confirm that PAR-4 expressed on
PTEC is functional. To determine the ability of KLK1 to activate
PAR-4, we performed cross desensitization studies using both
KLK1 and the PAR-4 agonist. PTEC pretreated with 100 nM
KLK1 for 10 min prior to the challenge of PAR-4 agonist showed
a reduced calcium response to PAR-4 agonist at 200 mM.
Pretreatment with a higher concentration of KLK1 (200 nM)
further attenuated PAR-4 agonist-induced calcium signaling in
PTEC (Fig. 7C), confirming that KLK1 activated PAR-4 and
desensitized it from the subsequent agonist stimulation. Finally, the
role of PAR-4 activation in KLK1-induced pro-inflammatory
responses was examined using specific PAR-4 antagonist. As
shown in Fig. 8, KLK1-induced CCL-2 and ICAM-1 mRNA and
protein expression were significantly reduced by pretreating PTEC
with 10 mM PAR-4 antagonist.
Discussion
Tubulointerstitial inflammation is a critical process in the
development of diabetic nephropathy [1,3,5]. Increased produc-
tion of reactive oxygen species, pro-inflammatory cytokines and
growth factors by resident and infiltrating cells are associated with
the development of tubulointerstitial lesions in both clinical and
experimental models of DN [3,4,34]. Although we and others have
previously shown that bradykinin up-regulated IL-6, CCL-2 and
TGF expression in cultured PTEC [9] and the application of
aprotinin, the KLK inhibitor, improved renal function of STZ-
Figure 8. PAR-4 mediated KLK1-induced pro-inflammatory responses in PTEC. Cells were untreated or pre-treated with 10 mM of the
selective PAR-4 antagonist, (tcY-NH2) for 1 h before treatment with 100 nM KLK1. Gene and protein expression was determined by real-time PCR and
ELISA respectively. The increase of KLK1-induced CCL-2 and ICAM-1 mRNA expression was significantly attenuated by PAR-4 antagonist (A) and the
increase of KLK-induced CCL-2, IL-8 and ICAM-1 protein expression was significantly reduced by PAR-4 antagonist (B). *p,0.05 compared with control
and #p,0.05; ##p,0.01 compared with cells incubated with KLK1 only.
doi:10.1371/journal.pone.0088894.g008
Figure 9. Schematic diagram illustrating the proposed activa-
tion of PAR-4 signaling by KLK1 in tubular inflammation. Under
the diabetic milieu, HG or AGE induces the expression of KLK1, which
leads to PAR-4 activation, intracellular Ca2+ mobilization and phos-
phorylation of MAPK signaling, and results in subsequent cytokine
production.
doi:10.1371/journal.pone.0088894.g009
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induced diabetic mice [35], the role of KKS in inflammatory
pathways leading to DN is still controversial. Some studies
demonstrated a protective effect of KLK1in reducing inflamma-
tion, renal fibrosis and glomerular hypertrophy in salt-induced
hypertensive rats [36], and improving cardiac function and
hypertension in experimental animal models [37,38].
In the present study, we examined the role of KLK1 in the pro-
inflammatory pathway of proximal tubular epithelial cells exposed
to the diabetic milieu. Considering that KLK1 expression was
induced by HG in cultured PTEC and increased in the proximal
tubules of human diabetic kidney tissue [9], we incubated PTEC
with recombinant KLK1 and showed that this serine protease
caused the activation of p42/44 and p38 MAPK signaling
pathways in renal tubular cells and increased the production of
inflammatory cytokines, IL-6, CCL-2, IL-8 and ICAM-1, that are
relevant to leukocyte recruitment to the interstitial space.
Furthermore, knockdown of endogenous KLK1 expression in
PTEC inhibited AGE-induced IL-8 and ICAM-1 expression,
suggesting that KLK1 mediated the pro-inflammatory responses
in diabetic-induced tubular injury.
Differential expression of KLK1 has been identified in several
cancers and other diseases [39]. Most of the physiological
functions of KLK1 are mediated by kinin receptor B1R and
B2R signaling, other studies demonstrated that KLK can
participate in direct cell signaling by cleavage and activation of
PARs [18,19,26]. Here, we showed that KLK1 up-regulated PAR-
4 expression, suggesting an interface between the kallikrein-kinin
system and coagulation system at the pro-inflammatory pathway
of renal tubular cells. The increased PAR-4 expression after
KLK1 incubation is consistent with the irreversible nature of PAR
activation, in which the activating protease cleaves the extracel-
lular N terminus to expose the tethered ligand, such that a fresh
supply of the receptor is required to sustain the action of its agonist
[20]. The activation of PAR-4 by KLK1 was ascertained by cross
desensitization studies in which cells pretreated with KLK1
showed reduced calcium signaling upon stimulation by the PAR-
4 agonist. Furthermore, the pro-inflammatory and pro-fibrotic
response triggered by KLK1 was also attenuated when PAR-4
signaling was blocked. Taken together, these results suggest that
KLK1 mediates tubular inflammation through PAR-4 activation.
The participation of PAR in DN was further demonstrated by
the up-regulation of PAR-2 and PAR-4 protein in human diabetic
kidney tissue. Increased PAR-2 and PAR-4 expression were
detected mostly in tubular cells and little expression was found in
glomerular areas. Increased renal PAR-2 expression was previ-
ously reported in the infiltrating cells and proximal tubuli of
patients with IgA nephropathy [22] as well as in the glomeruli of
diabetic db/db mice [33]. PAR-2 is a potent pro-inflammatory
mediator in keratinocytes [40] and kidney cells [33,41,42]. PAR-2
activation also triggers angiogenesis that contributes to tumor
growth and wound healing. However, few studies have examined
PAR-4 since the expression of this receptor is barely detectable in
many cell types. Here, we describe for the first time a markedly
increase in expression of PAR-4 after HG stimulation in PTEC
and in human diabetic kidney tissue, compared to PAR-1 and
PAR-2 expression, suggesting a role of PAR-4 in the pathogenesis
of DN.
Both thrombin and trypsin stimulate pro-inflammatory respons-
es via the activation of PAR in primary culture of human PTEC
[41,43], but not all the effects of thrombin could be reproduced by
the PAR-1 agonist, implying that other family members may be
involved in provoking these inflammatory responses in PTEC.
Several groups have reported the pro-inflammatory effect of PAR-
4 activation in endothelial cells [44,45], neutrophils [30] and
sensory neurons [46], and suggested that PAR-4 may play an
important role in the early event of inflammation including
leukocyte rolling and adhesion process [30,45,47]. Our data not
only revealed the cytokine-releasing function of PAR-4 in the
proximal tubular cells, but also demonstrated a PAR-4 mediated
pro-inflammatory pathway in response to HG stimulation. PAR-4
antagonist blocked HG-induced p42/44 MAPK phosphorylation
in PTEC and attenuated the downstream induction of pro-
inflammatory cytokines (IL-6 and CCL-2), pro-fibrotic factor
(CTGF) and collagen IV synthesis, indicating the involvement of
PAR-4 in this process via the activation of MAPK signaling.
Although both PAR-1 and PAR-4 are thrombin receptors, the
up-regulation of PAR-1 protein in the diabetic kidney is not
significant by immunohistochemical staining. This may be due to
the difference in receptor potencies and kinetics of desensitization.
PAR-1 responds to low enzyme concentration and mediates rapid
and transient activation, whereas PAR-4 only responds to high
enzyme concentration and causes a delayed and sustained
activation [20]. As a result, up-regulation of PAR-4 expression
may become more significant in prolonged stimulation as diabetic
nephropathy progress. In addition, PAR-2 is often co-expressed
with PAR-4 as they are both up-regulated by tumor necrosis
factor-a. A recent study also revealed the heterodimerization
between PAR-2 and PAR-4 proteins, suggesting the regulatory
role of PAR-2 in the membrane trafficking of PAR-4 [48].
To summarize, our results demonstrate for the first time the
pro-inflammatory effect of KLK1 on PTEC. As illustrated in
Fig. 9, it is likely that HG and AGE upregulate the expression of
KLK1, which is a serine protease capable of activating PAR-4,
leading to intracellular calcium mobilization, phosphorylation of
MAPK, and the subsequent cytokine synthesis. In fact, we propose
that KLK1 promotes tubular inflammation through the activation
of multiple receptors. In most studies, KLK1 targets B2R via the
formation of bradykinin (BK) [49] and we previously demonstrat-
ed this phenomenon in HG stimulated PTEC [9] although KLK1
was recently shown to directly activate B2R in the absence of
kininogen both in vitro [50] and in vivo [51] in other cell types.
However, application of B2R blocker, icatibant only partially
reduced HG-induced inflammatory responses and protected the
diabetic db/db mice from renal damage [9,52]. These data
support our hypothesis that multiple pathways are involved in the
inflammatory process under the diabetic condition. Interestingly,
recent studies from a rat paw inflammation model showed that
edema induced by PAR-4 agonist was blocked by B2R antagonist
[53], and PAR-4-induced sensitization of rat joint primary
afferents involved B2R activation [54], suggesting a crosstalk
between PAR-4 and B2R, but the mechanism remains unknown
and further investigation is needed to dissect the possible
association between these receptors in other cell types. In
conclusion, this study suggests a novel pathway in which KLK1
plays a role in tubular inflammation via the activation of PAR-4
and provides a potential therapeutic target for DN in the future.
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